基于整合药理学策略探讨泻白散治疗小儿肺炎的潜在机制
该研究采用网络药理学预测泻白散治疗小儿肺炎的活性成分与靶点,并用UPLC-Q/Orbitrap HRMS鉴定主要成分,结合分子对接、分子动力学模拟及巨噬细胞实验验证。结果显示泻白散可能通过调控NF-κB p65、Akt1和Caspase-3等靶点及IL-17、TNF、PI3K-Akt通路发挥抗炎与抗凋亡作用。
要点
- 泻白散可能通过槲皮素、山奈酚等成分作用于NF-κB p65、Akt1、Caspase-3等靶点。
- IL-17、TNF和PI3K-Akt信号通路可能是泻白散抗炎、免疫调节和抗凋亡的关键通路。
- 细胞实验显示泻白散抑制LPS诱导的NF-κB p65表达及IL-6、IL-1β产生,并调节Akt1/Caspase-3凋亡通路。
核心结论
- 泻白散治疗小儿肺炎的潜在机制涉及抗炎与抗凋亡作用,可能通过调控NF-κB p65、Akt1和Caspase-3等靶点及IL-17、TNF、PI3K-Akt通路实现。
研究设计与样本
- 采用网络药理学预测泻白散活性成分与靶点,并用UPLC-Q/Orbitrap HRMS分析主要成分。
- 进一步通过分子对接、分子动力学模拟及巨噬细胞实验进行验证。
主要发现
- 筛选出泻白散120个活性成分和128个潜在靶点,其中槲皮素、山奈酚、柚皮素、甘草查尔酮A和异鼠李素为最潜在成分。
- AKT1、MAPK3、VEGFA、TP53、JUN、PTGS2、CASP3、MAPK8和NF-κB p65为最潜在靶点。
- IL-17、TNF和PI3K-Akt信号通路为最可能被泻白散调控的通路,参与抗炎、免疫应答和凋亡过程。
- UPLC-Q/Orbitrap HRMS鉴定出甘草苷、槲皮素、山奈酚、甘草查尔酮A和甘草次酸。
- 分子对接显示槲皮素、山奈酚、甘草查尔酮A和甘草苷与NF-κB p65有良好结合能力,槲皮素和山奈酚与Akt1或Caspase-3有良好结合能力。
临床怎么用
- 泻白散抗炎作用可能与调控NF-κB p65及下游IL-6、IL-1β相关,抗凋亡作用可能与调节Akt1和Caspase-3相关。
- 网络药理学预测的活性成分和通路可为后续实验研究提供参考,但临床用药仍需遵循辨证论治。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Xiebai San (XBS) is a traditional Chinese medicine (TCM) prescription that has been widely used to treat pediatric pneumonia since the Song dynasty. To reveal its underlying working mechanism, a network pharmacology approach was used to predict the active ingredients and potential targets of XBS in treating pediatric pneumonia. As a result, 120 active ingredients of XBS and 128 potential targets were screened out. Among them, quercetin, kaempferol, naringenin, licochalcone A and isorhamnetin showed to be the most potential ingredients, while AKT1, MAPK3, VEGFA, TP53, JUN, PTGS2, CASP3, MAPK8 and NF-κB p65 showed to be the most potential targets. IL-17 signaling pathway, TNF signaling pathway and PI3K-Akt signaling pathway, which are involved in anti-inflammation processes, immune responses and apoptosis, showed to be the most probable pathways regulated by XBS. UPLC-Q/Orbitrap HRMS analysis was then performed to explore the main components of XBS, and liquiritin, quercetin, kaempferol, licochalcone A and glycyrrhetinic acid were identified. Molecular docking analysis of the compounds to inflammation-associated targets revealed good binding abilities of quercetin, kaempferol, licochalcone A and liquiritin to NF-κB p65 and of quercetin and kaempferol to Akt1 or Caspase-3. Moreover, molecular dynamics (MD) simulation for binding of quercetin or kaempferol to NF-κB p65 revealed dynamic properties of high stability, high flexibility and lowbinding free energy. In the experiment with macrophages, XBS markedly suppressed the (Lipopolysaccharides) LPS-induced expression of NF-κB p65 and the production of pro-inflammatory cytokines IL-6 and IL-1β, supporting XBS to achieve an anti-inflammatory effect through regulating NF-κB p65. XBS also down-regulated the expression of p-Akt (Ser473)/Akt, Bax and Caspase-3 and up-regulated the expression of Bcl-2, indicating that regulating Akt1 and Caspase-3 to achieve anti-apoptotic effect is also the mechanism of XBS for treating pediatric pneumonia. Our study helped to reveal the pharmacodynamics material basis as well as the mechanism of XBS in treating pediatric pneumonia.
引用
- Luo Z, Huang J, Li E, et al. An Integrated Pharmacology-Based Strategy to Investigate the Potential Mechanism of Xiebai San in Treating Pediatric Pneumonia. Front Pharmacol. 2022. PMID: 35237157. doi:10.3389/fphar.2022.784729
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。